Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah. |
Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease. Peer reviewed |
Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318 Peer Reviewed verified by ORBi |
Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Nguyen, N.-Q.-N. (2011). The antiangiogenic 16K prolactin impairs functional tumor neovascularization by affecting vessel maturation [Paper presentation]. Giga cancer, Liège, Belgium. |
Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium. |
Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Involvement of microRNAs in the regulation of angiogenesis by the antiangiogenic factor 16K [Poster presentation]. Biomedica, Liège, Belgium. |
Nguyen, N.-Q.-N. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Paper presentation]. Giga cancer, Liège, Belgium. |
Halkein, J., Malvaux, L., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2009). Regulation of microRNAs expression by the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium. |
Nguyen, N.-Q.-N., Lion, M., Blacher, S., Camby, S., Castermans, K., Noël, A., Martial, J., & Struman, I. (2009). The antiangiogenic factor 16K hPRL affects tumor vessel maturation [Poster presentation]. Giga cancer day, Liège, Belgium. |
Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. Cancer Letters, 284 (2), 222-228. doi:10.1016/j.canlet.2009.04.030 Peer Reviewed verified by ORBi |
Nguyen, N.-Q.-N., Camby, S., Lion, M., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the ability of 16K hPRL to affect tumor vessel maturation [Poster presentation]. Biomedica, liège, Belgium. |
Castermans, K., Nguyen, N.-Q.-N., Lecomte, J., Noël, A., Martial, J., & Struman, I. (2009). The contribution of vasculogenesis to tumor neovascularization after angiostatic treatment [Poster presentation]. Giga cancer day, liège, Belgium. |
Nguyen, N.-Q.-N., Camby, S., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Study of the effect of the antiangiogenic factor 16K hPRL in tumor vessel maturation [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Bozeman, United States - Montana. |
Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Bajou, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Big Sky, United States - Montana. |
Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (14 February 2008). Antiangiogenic peptides. |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294 Peer Reviewed verified by ORBi |
Martial, J., Struman, I., Nguyen, N.-Q.-N., Brasseur, R., & Lins, L. (02 May 2007). Antiangiogenic peptides. |
Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., Bonda, T., Schaefer, A., Sliwa, K., Forster, O., Quint, A., Landmesser, U., Doerries, C., Luchtefeld, M., Poli, V., Schneider, M. D., Balligand, J. L., Desjardins, F., Ansari, A., Struman, I., Nguyen, N.-Q.-N., Zschemisch, N. H., ... Drexler, H. (09 February 2007). A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128 (3), 589-600. doi:10.1016/j.cell.2006.12.036 Peer Reviewed verified by ORBi |
Kinet, V., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (2007). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia:Host cell response to cancer, Keystone, United States - Colorado. |
Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021 Peer Reviewed verified by ORBi |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana. |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island. |
Nguyen, N.-Q.-N. (2006). Study of the effect of the antiangiogenic factor 16K hPRL on tumor growth and metastasis and identification of new antiangiogenic peptides [Doctoral thesis, Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/314773 |
Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103 Peer Reviewed verified by ORBi |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California. |
Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515 Peer Reviewed verified by ORBi |
Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001 Peer Reviewed verified by ORBi |
Tabruyn, S., Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (14 May 2004). Molecular mechanisms involved in apoptosis and cell cycle arrest induced by the antiangiogenic factor 16K hPRL [Poster presentation]. Faseb meeting 2005. |
Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2004). The 16 kDa N-terminal fragment of the human prolactin. Design and production of minimal peptides retaining antiangiogenic and antitumoral properties [Poster presentation]. Association belge pour l’étude du cancer, Liège, Belgium. |
Nguyen, N.-Q.-N., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). Design and production of minimal peptides that retain antiangiogenic and antitumoral properties of the 16K N-terminal fragment of the human prolactin [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France. |